期刊文献+

转化治疗在晚期胃癌中的应用 被引量:3

Application of conversion therapy in advanced gastric cancer
下载PDF
导出
摘要 晚期胃癌生存期短,预后差,目前的指南均推荐姑息性治疗为主.而鉴于转化治疗在结直肠癌肝转移治疗上的成功,其对于晚期胃癌也有着相似的启示.一些小样本的研究发现转化治疗能给晚期胃癌患者带来较姑息治疗显著的生存期提高,而由于目前转治化疗在晚期胃癌的应用上尚缺乏有效的循证医学证据,多学科协作组(multidisciplinary team,MDT)模式是当前的晚期胃癌转化治疗的重要保障.晚期胃癌的转化往往需要多个学科配合的综合治疗,本文更多的从非外科角度上对转化治疗在病例、治疗方案和治疗时机的选择进行全面论述,旨在为临床治疗提供参考. Patients with advanced gastric cancer(AGC) have short overall survival and poor prognosis. Current guidelines recommend palliative treatments. The success of conversion therapy in liver metastases of colorectal cancer gives an inspiration to AGC treatment. Some small sample studies indicated that conversion therapy provided AGC patients longer overall survival time compared to those who received palliative treatments. The application of conversion therapy in AGC is still lack of effective evidence of evidence-based medicine. The multidisciplinary team(MDT) mode is an important guarantee for the conversion therapy of AGC. The conversion therapy of AGC requires multi-disciplinary comprehensive treatment. This article makes a comprehensive discussion on the choice of cases, treatment plans and timing of treatment from the perspective of nonsurgical treatment, with an aim to provide a reference for clinical treatments.
出处 《世界华人消化杂志》 CAS 2016年第18期2830-2837,共8页 World Chinese Journal of Digestology
基金 上海市中医药事业发展三年行动计划基金资助项目 No.ZY3-CCCX-3-2003~~
关键词 胃癌 转化治疗 多学科综合治疗 Gastric cancer Conversion therapy Multidisciplinary treatment
  • 相关文献

参考文献2

二级参考文献50

  • 1[1]Rowinsky EK,Donehower RC.Paclitaxel (taxol) N Engl J Med 1995; 332:1004-1014
  • 2[2]Chang YF,Li LL,Wu CW,Liu TY,Lui WY,P'eng FK,Chi CW.Paclitaxel-induced apoptosis in human gastric carcinoma cell lines.Cancer 1996; 77:14-18
  • 3[3]Kim YH,Shin SW,Kim BS,Kim JH,Kim JG,Mok YJ,Kim CS,Rhyu HS,Hyun JH,Kim JS.Paclitaxel,5-fluorouracil,and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma.Cancer 1999; 85:295-301
  • 4[4]Murad AM,Petroianu A,Guimaraes RC,Aragao BC,Cabral LO,Scalabrini-Neto AO.Phase Ⅱ trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer:a novel,safe,and effective regimen.Am J Clin Oncol 1999; 22:580-586
  • 5[5]Lokich JJ,Sonneborn H,Anderson NR,Bern MM,Coco FV,Dow E,Oliynyk P.Combined paclitaxel,cisplatin,and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas.Cancer 1999; 85:2347-2351
  • 6[6]Kollmannsberger C,Quietzsch D,Haag C,Lingenfelser T,Schroeder M,Hartmann JT,Baronius W,Hempel V,Clemens M,Kanz L,Bokemeyer C.A phase Ⅱ study of paclitaxel,weekly,24-hour continous infusion 5-fluorouracil,folinic acid and cisplatin in patients with advanced gastric cancer.Br J Cancer 2000; 83:458-462
  • 7[7]Garcia AA,Leichman CG,Lenz HJ,Baranda J,Lujan R,Casagrande Y,Leichman L.Phase Ⅱ trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic,measurable adenocarcinoma of the stomach.Jpn J Clin Oncol 2001; 31:275-278
  • 8[8]Yamada Y,Shirao K,Ohtsu A,Boku N,Hyodo I,Saitoh H,Miyata Y,Taguchi T.Phase Ⅱ trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions.Ann Oncol 2001; 12:1133-1137
  • 9[9]Wiernik PH,Schwartz EL,Einzig A,Strauman JJ,Lipton RB,Dutcher JP.Phase Ⅰ trial of taxol given as a 24-hour infusion every 21 days:responses observed in metastatic melanoma.J Clin Oncol 1987; 5:1232-1239
  • 10[10]Los G,Mutsaers PH,van der Vijgh WJ,Baldew GS,de Graaf PW,McVie JG.Direct diffusion of cis-diamminedichloroplatinum (Ⅱ) in intraperitoneal rat tumors after intraperitoneal chemotherapy:a comparison with systemic chemotherapy.Cancer Res 1989; 49:3380-3384

共引文献28

同被引文献11

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部